CD81 as target for B cell lymphomas

In this issue of JEM, Vences-Catalán et al. (https://doi.org/10.1084/jem.20190186) demonstrate that a particular anti-CD81 antibody shows promising features as a novel immunotherapeutic tool to treat B cell lymphomas. Surprisingly, although CD81 is widely expressed, only minor side effects on other...

Descripción completa

Detalles Bibliográficos
Autor principal: Küppers, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2019
Materias:
News
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605746/
https://www.ncbi.nlm.nih.gov/pubmed/31171705
http://dx.doi.org/10.1084/jem.20190733
_version_ 1783431823322251264
author Küppers, Ralf
author_facet Küppers, Ralf
author_sort Küppers, Ralf
collection PubMed
description In this issue of JEM, Vences-Catalán et al. (https://doi.org/10.1084/jem.20190186) demonstrate that a particular anti-CD81 antibody shows promising features as a novel immunotherapeutic tool to treat B cell lymphomas. Surprisingly, although CD81 is widely expressed, only minor side effects on other CD81(+) immune cells analyzed were observed.
format Online
Article
Text
id pubmed-6605746
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-66057462020-01-01 CD81 as target for B cell lymphomas Küppers, Ralf J Exp Med News In this issue of JEM, Vences-Catalán et al. (https://doi.org/10.1084/jem.20190186) demonstrate that a particular anti-CD81 antibody shows promising features as a novel immunotherapeutic tool to treat B cell lymphomas. Surprisingly, although CD81 is widely expressed, only minor side effects on other CD81(+) immune cells analyzed were observed. Rockefeller University Press 2019-07-01 2019-06-06 /pmc/articles/PMC6605746/ /pubmed/31171705 http://dx.doi.org/10.1084/jem.20190733 Text en © 2019 Küppers http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle News
Küppers, Ralf
CD81 as target for B cell lymphomas
title CD81 as target for B cell lymphomas
title_full CD81 as target for B cell lymphomas
title_fullStr CD81 as target for B cell lymphomas
title_full_unstemmed CD81 as target for B cell lymphomas
title_short CD81 as target for B cell lymphomas
title_sort cd81 as target for b cell lymphomas
topic News
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605746/
https://www.ncbi.nlm.nih.gov/pubmed/31171705
http://dx.doi.org/10.1084/jem.20190733
work_keys_str_mv AT kuppersralf cd81astargetforbcelllymphomas

Ejemplares similares